The company announced this on Thursday in Cambridge (US state of Massachusetts).
Moderna now expects sales from pre-agreed purchase agreements for the corona vaccine to be around $18 billion to $19 billion in 2022. The group had previously pledged about $21 billion.
For Moderna, the corona pandemic tailwind could likely abate further in 2023: According to the company, only $4.5 to $5.5 billion worth of acquisition deals have been signed so far – up to three billion attributable to delayed deliveries. However, management expects more – unspecified – sales in the most important sales markets.
In the third quarter, the group fell short of analysts’ expectations: Sales fell by a third to $3.1 billion. As a result, Moderna earned $1.04 billion – profits more than tripled a year ago.
(SDA)
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
